CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine

Cannabis Bioscience International Holdings (OTC Pink: CBIH) announced an expanded research strategy at the intersection of endocannabinoid science and biological medicine. The company plans to investigate cannabinoids' interactions with pathways tied to immune regulation, neuroinflammation, chronic pain, autoimmune disease, and cancer biology, with an eye toward building a patentable IP portfolio.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.